Corrigendum: The Regulators Associated With N6-Methyladenosine in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Reveal New Clinical and Prognostic Markers

Front Cell Dev Biol. 2022 Mar 7:10:843275. doi: 10.3389/fcell.2022.843275. eCollection 2022.

Shuzhen Tan^{1

2}, Zesong Li³, Kai Li², Yingqi Li², Guosheng Liang², Zhenye Tang², Jianhao Kang², Wenqing Chen², Minhua Li², Zhilin Zou², Guoliang Pi⁴, Xiao Zhu^{1

2

3}

¹ School of Laboratory Medicine, Hangzhou Medical College, Hangzhou, China.
² Southern Marine Science and Engineering Guangdong Laboratory (Zhanjiang), Guangdong Medical University, Zhanjiang, China.
³ Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital (Shenzhen Institute of Translational Medicine), Shenzhen, China.
⁴ Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

[This corrects the article DOI: 10.3389/fcell.2021.741521.].

Keywords: N6-methyladenosine; lung cancer; prognosis; regulators; risk scores.